NCT03000257 2022-04-14
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Completed
Clinical Trials
11 trialsNCT03086239 2021-08-03
A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer
AbbVie
Phase 1 Completed
NCT02674568 2021-07-30
TRINITY
AbbVie
Phase 2 Completed
NCT03033511 2021-07-29
MERU
AbbVie
Phase 3 Terminated
NCT03061812 2021-02-23
TAHOE
AbbVie
Phase 3 Completed
NCT03543358 2021-01-05
A Long-Term Study of Rovalpituzumab Tesirine
AbbVie
Phase 2 Completed
NCT03026166 2020-07-17
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
AbbVie
Phase 1/2 Terminated
NCT02819999 2020-03-12
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
AbbVie
Phase 1 Terminated
NCT03503890 2019-09-10
Expanded Access to Rovalpituzumab Tesirine
AbbVie
No longer available
NCT03334487 2018-12-26
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Withdrawn
NCT01901653 2018-08-09
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Stemcentrx
Phase 1/2 Completed